Sugi Predict

Sugi Predict / Compounds / SCHEMBL1979026

SCHEMBL1979026

SCHEMBL1979026

CN(C)CCNC(=O)OC(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.55
▸ MEN1 O00255 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ CA12 O43570 5/20 0.45
▸ CA1 P00915 5/20 0.45
▸ CA2 P00918 4/20 0.45
▸ CA9 Q16790 4/20 0.45
▸ EPHX1 P07099 1/20 0.45
▸ CKS1B P61024 1/20 0.45
▸ SKP1 P63208 1/20 0.45
▸ SKP2 Q13309 1/20 0.45
▸ MALT1 Q9UDY8 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ DNM1 Q05193 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4111565 0.89 TDP1 (0.49) TDP1MEN1GAAKMT2AMAOA
SCHEMBL285008 0.89 TDP1 (0.66) TDP1MEN1GAAKMT2AMAOA
SCHEMBL13055395 0.88 TDP1 (0.55) TDP1MEN1GAAKMT2AMAOA
SCHEMBL21197815 0.88 TDP1 (0.44) TDP1MEN1GAAKMT2AMAOA
SCHEMBL15680567 0.87 TDP1 (0.64) TDP1MEN1GAAKMT2AMAOA
SCHEMBL4129046 0.86 MAOA (0.55) TDP1MEN1GAAKMT2AMAOA
SCHEMBL12482641 0.86 TDP1 (0.56) TDP1MEN1GAAKMT2AMAOA
SCHEMBL34463500 0.85 TDP1 (0.67) TDP1MEN1GAAKMT2AMAOA
SCHEMBL24224621 0.85 TDP1 (0.51) TDP1MEN1GAAKMT2AMAOA
SCHEMBL20812668 0.85 TDP1 (0.51) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117385499-B Preparation process of polyurethane-nylon composite fiber material 烟台云泷化学制品有限公司 2024-02-13 — — CN claimed
CN-117385499-A Preparation process of polyurethane-nylon composite fiber material 烟台云泷化学制品有限公司 2024-01-12 — — CN claimed
CN-114144410-A Polyarylurea derivatives and their use in the treatment of muscular diseases 阿纳格纳斯生物技术股份有限公司 2022-03-04 — — CN claimed
CN-118159533-A Heterocyclic compounds and their use 艾森医药有限公司 2024-06-07 — — CN disclosed
CN-117385499-B Preparation process of polyurethane-nylon composite fiber material 烟台云泷化学制品有限公司 2024-02-13 — — CN disclosed
CN-117385499-A Preparation process of polyurethane-nylon composite fiber material 烟台云泷化学制品有限公司 2024-01-12 — — CN disclosed
CN-117098765-A Heterocyclic derivatives as Janus kinase inhibitors 奇斯药制品公司 2023-11-21 — — CN disclosed
US-20230165932-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-06-01 — — US disclosed
CN-114144410-A Polyarylurea derivatives and their use in the treatment of muscular diseases 阿纳格纳斯生物技术股份有限公司 2022-03-04 — — CN disclosed
US-20210069288-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2021-03-11 — — US disclosed
WO-2021041770-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2021-03-04 — — WO disclosed
US-8034376-B2 Lipid containing formulations Alnylam Pharamaceticals, Inc. (US) 2011-10-11 — — US disclosed
WO-2011071565-A1 TGR5 AGONISTS EXELIXIS, INC. (US) 2011-06-16 — — WO disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed
US-20090023673-A1 LIPID CONTAINING FORMULATIONS BANK OF AMERICA, N.A. 2009-01-22 — — US disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 — — EP disclosed
US-20050271615-A1 Self-immolative dendrimers releasing many active moieties upon a single activating event RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2005-12-08 — — US disclosed
WO-2004019993-A1 SELF-IMMOLATIVE DENDRIMERS RELEASING MANY ACTIVE MOIETIES UPON A SINGLE ACTIVATING EVENT RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2004-03-11 — — WO disclosed
US-5693619-A ENZYME INHIBITORS; ADMINISTERED TO TREAT CONGESTIVE HEART FAILURE AND HYPERTENSION BOEHRINGER INGELHEIM (CANADA), LTD. (CA) 1997-12-02 — — US disclosed
EP-0300189-A2 New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-01-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210069288-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 TDP1 2636/4885MEN1 1646/4885GAA 482/4885
US-20230165932-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 TDP1 2636/4885MEN1 1646/4885GAA 482/4885
US-20090023673-A1 LIPID CONTAINING FORMULATIONS LIPA, POLRMT, PHOSPHO1 TDP1 586/4885MEN1 1699/4885GAA 1119/4885
US-20050271615-A1 Self-immolative dendrimers releasing many active moieties upon a single activating event CASP9, BID, APAF1 TDP1 212/4885MEN1 2375/4885GAA 149/4885
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 TDP1 1881/4885MEN1 4778/4885GAA 3904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.